These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1091 related items for PubMed ID: 23332622

  • 1. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M.
    Med Clin (Barc); 2013 Aug 17; 141(4):167-74. PubMed ID: 23332622
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.
    Diabetes Obes Metab; 2013 Aug 17; 15(8):737-49. PubMed ID: 23433305
    [Abstract] [Full Text] [Related]

  • 4. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.
    BMJ; 2012 Jan 10; 344():d7771. PubMed ID: 22236411
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M, Harris K, Brackett A.
    Ann Pharmacother; 2012 Jan 10; 46(1):68-78. PubMed ID: 22232377
    [Abstract] [Full Text] [Related]

  • 6. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ.
    Expert Opin Emerg Drugs; 2004 May 10; 9(1):155-66. PubMed ID: 15155141
    [Abstract] [Full Text] [Related]

  • 7. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH.
    Curr Med Res Opin; 2016 May 10; 32(1):61-76. PubMed ID: 26439329
    [Abstract] [Full Text] [Related]

  • 8. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
    González C, Beruto V, Keller G, Santoro S, Di Girolamo G.
    Expert Opin Investig Drugs; 2006 Aug 10; 15(8):887-95. PubMed ID: 16859392
    [Abstract] [Full Text] [Related]

  • 9. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Scheen AJ.
    Rev Med Liege; 2007 Apr 10; 62(4):217-21. PubMed ID: 17566392
    [Abstract] [Full Text] [Related]

  • 10. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec 10; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 11. Emerging GLP-1 receptor agonists.
    Lund A, Knop FK, Vilsbøll T.
    Expert Opin Emerg Drugs; 2011 Dec 10; 16(4):607-18. PubMed ID: 21905764
    [Abstract] [Full Text] [Related]

  • 12. [Glucagon-like peptide 1 (GLP-1)].
    Parhofer KG.
    MMW Fortschr Med; 2007 Jun 21; 149(25-26):41-3. PubMed ID: 17713050
    [Abstract] [Full Text] [Related]

  • 13. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
    Meier JJ.
    Nat Rev Endocrinol; 2012 Dec 21; 8(12):728-42. PubMed ID: 22945360
    [Abstract] [Full Text] [Related]

  • 14. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
    Lorber D.
    Cardiovasc Ther; 2013 Aug 21; 31(4):238-49. PubMed ID: 23865382
    [Abstract] [Full Text] [Related]

  • 15. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
    Gallwitz B.
    Drugs; 2011 Sep 10; 71(13):1675-88. PubMed ID: 21902291
    [Abstract] [Full Text] [Related]

  • 16. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J, Gallwitz B.
    Diabetes Obes Metab; 2014 Aug 10; 16(8):673-88. PubMed ID: 24373150
    [Abstract] [Full Text] [Related]

  • 17. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
    Mundil D, Cameron-Vendrig A, Husain M.
    Diab Vasc Dis Res; 2012 Apr 10; 9(2):95-108. PubMed ID: 22496442
    [Abstract] [Full Text] [Related]

  • 18. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
    Fernández-García JC, Colomo N, Tinahones FJ.
    Med Clin (Barc); 2014 Apr 10; 143 Suppl 2():18-22. PubMed ID: 25326839
    [Abstract] [Full Text] [Related]

  • 19. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL, Garber A.
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr 10; 20(2):87-97. PubMed ID: 23403741
    [Abstract] [Full Text] [Related]

  • 20. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S.
    Diabetes Res Clin Pract; 2015 Oct 10; 110(1):26-37. PubMed ID: 26358202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.